Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists

被引:21
|
作者
Liedtke, S
Flau, K
Kathmann, M
Schlicker, E
Stark, H
Meier, G
Schunack, W
机构
[1] Univ Bonn, Inst Pharmakol & Toxikol, D-53113 Bonn, Germany
[2] Univ Frankfurt, Inst Pharmazeut Chem, D-60439 Frankfurt, Germany
[3] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany
关键词
histamine H-3 receptors; S-35]GTP gamma S binding; H-3]N-alpha-methylhistamine binding; noradrenaline release; mouse brain cortex; partial agonists; non-imidazole H-3-receptor antagonists; presynaptic receptors;
D O I
10.1007/s00210-002-0649-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined whether replacement of imidazole by a piperidine or pyrrolidine moiety will affect the potency and affinity of six H-3-receptor antagonists. Potencies were determined in superfused mouse brain cortex slices preincubated with [H-3]noradrenaline, in which the interaction of the antagonists with histamine with respect to its inhibitory effect on the electrically evoked tritium overflow was studied. Affinities were determined in mouse brain cortex membranes, using the radioligand [H-3]N-alpha-methylhistamine. The concentration-response curve of histamine for its effect on the evoked overflow from mouse brain cortex slices was shifted to the right by the 13 compounds under study. Replacement of the imidazole by a piperidine ring affected the pA(2) value as follows: thioperamide, -2.7 log units; clobenpropit, -1.9; proxyfan, -1.3; FUB 138, -1.2. Potency hardly changed (less than or equal to0.4 log units) when imidazole was replaced by piperidine in FUB 181 and by piperidine or pyrrolidine in FUB 153. Binding of [H-3]N-alpha-methylhistamine to mouse brain cortex membranes was inhibited monophasically by all compounds. The pK(i) values closely matched their pA2 values with three exceptions. The pKi values of proxyfan, FUB 138, and FUB 153 exceeded their respective pA2 values by about 1 log unit. To reveal a potential partial agonism, the effect of the three drugs on (1) the electrically evoked tritium overflow and (2) [S-35]GTPgammaS binding in mouse cortex preparations was determined. Proxyfan proved to be a partial agonist in both models (with intrinsic activities of 0.2 and 0.3, respectively) whereas FUB 138 and FUB 153 were devoid of agonistic effects. In conclusion, replacement of imidazole by piperidine or pyrrolidine affects the antagonist potencies of six H-3-receptor antagonists in a very different manner. The piperidine analogue of FUB 181 (with a pA(2) value as high as 7.7) may represent a lead for the development of non-imidazole H3-receptor antagonists. The discrepancy between the pK(i) and pA(2) values may be accounted for by partial agonism in the case of proxyfan but can, at present, not be satisfactorily explained with respect to FUB 138 and FUB 153.
引用
下载
收藏
页码:43 / 50
页数:8
相关论文
共 50 条
  • [21] Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain
    Sadek, B
    Elz, S
    Pertz, HH
    Stark, H
    Schunack, W
    INFLAMMATION RESEARCH, 2004, 53 (Suppl 2) : S109 - S115
  • [22] Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain
    B. Sadek
    S. Elz
    H. H. Pertz
    H. Stark
    W. Schunack
    Inflammation Research, 2004, 53 : S109 - S115
  • [23] New histamine H3-receptor ligands of the proxifan series:: Imoproxifan and other selective antagonists with high oral in vivo potency
    Sasse, A
    Sadek, B
    Ligneau, X
    Elz, S
    Pertz, HH
    Luger, P
    Ganellin, CR
    Arrang, JM
    Schwartz, JC
    Schunack, W
    Stark, H
    JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (17) : 3335 - 3343
  • [24] Functional evaluation of histamine H3-receptor antagonists in human saphenous vein.
    Valentine, AF
    Rizzo, CA
    Rivelli, MA
    Hey, JA
    FASEB JOURNAL, 1998, 12 (05): : A702 - A702
  • [25] From histamine to imidazolylalkyl-sulfonamides:: The design of a novel series of histamine H3-receptor antagonists.
    Tozer, MJ
    Harper, EA
    Kalindjian, SB
    Pether, MJ
    Shankley, NP
    Watt, GF
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (13) : 1825 - 1830
  • [26] Non-imidazole heterocyclic histamine H3 receptor antagonists
    Chai, WY
    Breitenbucher, JG
    Kwok, A
    Li, XB
    Wong, V
    Carruthers, NI
    Lovenberg, TW
    Mazur, C
    Wilson, SJ
    Axe, FU
    Jones, TK
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (10) : 1767 - 1770
  • [27] Fluorinated non-imidazole histamine H3 receptor antagonists
    Isensee, K.
    Amon, M.
    Galaparti, A.
    Ligneau, X.
    Camelin, J. -C.
    Capet, M.
    Schwartz, J. -C.
    Stark, H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2172 - 2175
  • [28] Ciproxifan and chemically related compounds are highly potent and selective histamine H3-receptor antagonists
    Kathmann, M
    Schlicker, E
    Marr, L
    Werthwein, S
    Stark, H
    Schunack, W
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (06) : 623 - 627
  • [29] Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists
    Stark, H
    Ligneau, X
    Sadek, B
    Ganellin, CR
    Arrang, JM
    Schwartz, JC
    Schunack, W
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (20) : 2379 - 2382
  • [30] Central Histamine, the H3-Receptor and Obesity Therapy
    Diaz, Nestor F.
    Flores-Herrera, Hector
    Garcia-Lopez, Guadalupe
    Molina-Hernandez, Anayansi
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (07) : 516 - 522